“Undiagnosed sleep apnea causes poor sleep and daytime tiredness, and can have a major impact on a person’s health.
SLEEPYHEAD CPAP APP DOWNLOAD
“We are excited to announce that SleepCheck will soon be available to download on the App Store,” said Tony Keating, CEO and Managing Director of ResApp. Last July, Sydney-based digital health company Sleepfit partnered with digital health engagement platform dacadoo to integrate sleep goals designed by Sleepfit on dacadoo. This integration will allow clinicians using Coviu’s platform to perform a remote respiratory assessment using ResApp’s clinically validated and Therapeutic Goods Administration (TGA) approved diagnostic test. The company also recently completed an initial integration of its ResAppDx-EU into Australian startup Coviu’s telehealth platform. In February, ResApp announced it has raised $5 million to drive forward its European commercialization, MobiHealthNews reported. Deloitte Access Economics estimates that OSA costs the Australian economy $21.2 billion annually. Untreated, sleep apnea has been linked to serious complications such as heart disease, hypertension, stroke and type 2 diabetes, and has a major impact on population health. Studies have shown that 80% of people with sleep apnea are undiagnosed.
In severe cases, this can happen more than 30 times per hour. Sleep apnea is when air stops flowing to one’s lungs for ten seconds or longer during sleep creating an ‘apnea’ event. Sleep apnea is the most common sleep breathing disorder affecting more than three in every ten men and nearly two in every ten women.
SLEEPYHEAD CPAP APP FULL
SleepCheck does not provide a diagnosis and is not intended as a substitute for a full sleep study using polysomnography. SleepCheck will soon be listed on the Australian Register of Therapeutic Goods (ARTG). SleepCheck is CE marked as a Class I medical device, which means it conforms to all European regulatory standards. In a 238 patient clinical study, ResApp’s algorithms correctly identified patients with OSA with sensitivities of 85% (mild OSA), 83% (moderate OSA) and 83% (severe OSA), and specificities of 73%, 80% and 90% when compared to an American Academy of Sleep Medicine (AASM) Type II sleep study (full, but unattended polysomnography) performed simultaneously in the patient’s home.
The app requires no accessories or hardware other than the user’s smartphone. To be used directly by consumers, SleepCheck is a smartphone app which uses clinically accurate algorithms to assess a person’s risk of OSA by analyzing their breathing and snoring sounds during sleep.
SLEEPYHEAD CPAP APP ANDROID
The company said it plans to launch SleepCheck for iOS on the App Store in the United Kingdom and Australia in the second quarter of this calendar year, with availability in additional countries and an Android version to follow. Brisbane-based ResApp, which creates smartphone apps for the diagnosis and management of respiratory diseases, last week announced its plans to launch SleepCheck, an at-home obstructive sleep apnoea (OSA) screening app.